5-HTP induced diarrhea as a carcinoid syndrome model in mice?

Fundamental and Clinical Pharmacology

Volumn 10, Issue 5, 1996, Pages 450-457

  Bourin, M ^a   Hascoet, M ^a   Deguiral, P ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

5 HTP; Animal model; Carcinoid syndrome; Mice

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2 METHYLSEROTONIN; 5 HYDROXYTRYPTOPHAN; BENSERAZIDE; BENZAMIDE DERIVATIVE; BUSPIRONE; CISAPRIDE; CYPROHEPTADINE; DECARBOXYLASE INHIBITOR; GRANISETRON; KETANSERIN; METHYSERGIDE; METOCLOPRAMIDE; MIANSERIN; ONDANSETRON; RITANSERIN; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST; TROPISETRON; ZACOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOID SYNDROME; CONTROLLED STUDY; DEFECATION; DIARRHEA; DRUG ANTAGONISM; DRUG METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029765085     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1996.tb00600.x     Document Type: Article

References (35)

1. Ahlman H. Serotonin and carcinoid tumors. J Cardiovasc Pharmacol 1985;7:S79-85
2. Anderson JV, Coupe MO, Morris JA. Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist. Br Med J 1987;294:1129
3. 4 receptors: a place in the sun. TiPS 1992;13:141-5
4. 4 receptors; potential therapeutic implications in neurology and psychiatry. CNS Drugs 1994;1:6-15
5. Boissier JR, Simon P. Action de la caféine sur la motilité de la souris. Arch Int Pharmacodyn 1965;158:212-21
6. Buchheit KH, Engel G, Mutschler E, Richardson B. Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol 1985;329: 36-41
7. 3 receptors. Br J Pharmacol 1988;94:397-412
8. 3 receptors in three isolated preparations derived from guinea-pig tissues. Br J Pharmacol 1990;101:591-8
9. Costall B, Naylor RJ. 5-hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol 1990;25:769-87
10. 3) receptor antagonist ICS 205-930 in the carcinoid syndrome. Aliment Pharmacol Ther 1982;2:167-72
11. Coupe M, Levi S, Ellis M. Therapy for symptoms in the carcinoid syndrome. Q J Med 1989;73:1021-36
12. Dumuis A, Bouhelal R, Sebben M. A non classical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the nervous system. Mol Pharmacol 1988;34: 880-7
13. 3 and atypical 5-HT receptors mediating guinea-pig ileal contractions in vitro. Br J Pharmacol 1990; 101:513-20
14. Fargeas MJ, Theodourou V, Fioramonti J, Bueno L. Relationship between mast cell degranulation and jejunal myoelectric alterations in intestinal anaphylaxis in rats. Gastroenterology 1992;102:157-62
15. Feniuk W. An analysis of 5-hydroxytryptamine receptors mediating contraction of isolated smooth muscle. Neuropharmacology 1984;23:1461-72
16. 1A receptors. Br J Pharmacol 1985; 86:601p
17. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol 1957;12:323-8
18. 1 receptors in myenteric and submucosal neurons. Am J Physiol 1988;255:603-11
19. 3 model displayed by 5HTP per os. Biol Psychiatry 1991;29:586-S
20. Gustafsen J, Lendorf A, Raskov H, Boesby S. Ketanserin versus placebo in carcinoid syndrome. Scand J Gastroenterol 1986;21:816-8
21. Hegde SS, Moy TM, Perry MR, Loch M, Eglen RM. Evidence for the involvement of 5-hydroxytryptamine 4 receptors in 5-hydroxytryptophan-induced diarrhea in mice. J Pharmacol Exp Ther 1994;271:741-7
22. Hendrix TR, Atkinson M, Clifton JA, Ingelfinger FJ. The effect of 5-hydroxytryptamine on intestinal motor function in man. Am J Med 1957;23:886-93
23. 4 receptor dual antagonist, on colonic function in vivo. J Pharmacol Exp Ther 1993;266:74-80
24. Krowicki, Hornby PJ. Serotonin microinjected into the nucleus raphe obscurus increases intragastric pressure in the rat via a vagally mediated pathway. J Pharmacol Exp Ther 1993;265:468-76
25. Leijsma MK, Kleibeuker JH, Sleijfer DT. Effects of ondansetron on symptoms and gastric emptying in carcinoid patients. Proc Am Soc Clin Oncol 1994;13: 190
26. Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1503-22
27. Oosterbosch L, Von der Ohe MR, Valdovinos MA, Kost LJ, Phillips SF, Camilleri M. Effects of serotonin on rat ileocolonic transit and fluid transfer in vivo: possible mechanism of action. Gut 1993;34:794-8
28. Ormsbee HS, Barone FC, Barnette MS. SKF 103829, a novel serotoninergic agent that contracts the lower oesophageal sphincter. Gastroenterology 1987;92:1562
29. Ortmann R, Waldemeier PC, Radeke E, Felner A, Delini-Stula A. The effect of a 5-HT uptake and MAO inhibitors on L5HTP induced exitation in rats. Naunyn Schmiedebergs Arch Pharmacol 1980;311:185-92
30. Platt AJ, Heddle RM, Rake MO. Ondansetron in carcinoid syndrome. Lancet 1992;339:1416
31. Sloviter RS, Drust EG, Conner JD. Specificity of a rat behavioral model for serotonin receptor activation. J Pharmacol Exp Psychiatry 1978;206:339-47
32. 3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1991;477-80
33. Von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Eng J Med 1993;329:1073-8
34. Von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of post prandial colonic tonic and phasic responses in humans. Gut 1994;35:536-41
35. Zifa E, Fillion G. 5-hydroxytryptamine receptors. Pharmacol Rev 1992;44:401-58